JP6356907B2 - アナモレリンに基づく医療 - Google Patents

アナモレリンに基づく医療 Download PDF

Info

Publication number
JP6356907B2
JP6356907B2 JP2017512679A JP2017512679A JP6356907B2 JP 6356907 B2 JP6356907 B2 JP 6356907B2 JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017512679 A JP2017512679 A JP 2017512679A JP 6356907 B2 JP6356907 B2 JP 6356907B2
Authority
JP
Japan
Prior art keywords
anamorelin
patient
pharmaceutical composition
patients
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017512679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526695A (ja
JP2017526695A5 (cg-RX-API-DMAC7.html
Inventor
マン ウィリアム
マン ウィリアム
フレンド ジョン
フレンド ジョン
ポルビーノ ウィリアム
ポルビーノ ウィリアム
アレン スーザン
アレン スーザン
ルゥ ミーン
ルゥ ミーン
デュウス エリザベス
デュウス エリザベス
ジョルジーノ ルーベン
ジョルジーノ ルーベン
バローニ エンリコ
バローニ エンリコ
Original Assignee
ヘルシン ヘルスケア ソシエテ アノニム
ヘルシン ヘルスケア ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6356907(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヘルシン ヘルスケア ソシエテ アノニム, ヘルシン ヘルスケア ソシエテ アノニム filed Critical ヘルシン ヘルスケア ソシエテ アノニム
Publication of JP2017526695A publication Critical patent/JP2017526695A/ja
Publication of JP2017526695A5 publication Critical patent/JP2017526695A5/ja
Priority to JP2018113592A priority Critical patent/JP6923486B2/ja
Application granted granted Critical
Publication of JP6356907B2 publication Critical patent/JP6356907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017512679A 2014-09-04 2015-08-28 アナモレリンに基づく医療 Active JP6356907B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018113592A JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018113592A Division JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Publications (3)

Publication Number Publication Date
JP2017526695A JP2017526695A (ja) 2017-09-14
JP2017526695A5 JP2017526695A5 (cg-RX-API-DMAC7.html) 2017-10-26
JP6356907B2 true JP6356907B2 (ja) 2018-07-11

Family

ID=55436476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512679A Active JP6356907B2 (ja) 2014-09-04 2015-08-28 アナモレリンに基づく医療
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Country Status (44)

Country Link
US (5) US9675600B2 (cg-RX-API-DMAC7.html)
EP (2) EP3188599B1 (cg-RX-API-DMAC7.html)
JP (3) JP6356907B2 (cg-RX-API-DMAC7.html)
KR (3) KR102234319B1 (cg-RX-API-DMAC7.html)
CN (5) CN113577073A (cg-RX-API-DMAC7.html)
AP (1) AP2017009772A0 (cg-RX-API-DMAC7.html)
AR (1) AR103118A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015312231B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003552A2 (cg-RX-API-DMAC7.html)
CA (1) CA2959158A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000494A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003263A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170121A (cg-RX-API-DMAC7.html)
CY (1) CY1122746T1 (cg-RX-API-DMAC7.html)
DK (1) DK3188599T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000055A (cg-RX-API-DMAC7.html)
EA (1) EA035578B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17019893A (cg-RX-API-DMAC7.html)
ES (1) ES2761777T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20186939B (cg-RX-API-DMAC7.html)
HR (1) HRP20192345T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046894T2 (cg-RX-API-DMAC7.html)
IL (1) IL250692B (cg-RX-API-DMAC7.html)
JO (1) JO3541B1 (cg-RX-API-DMAC7.html)
LT (1) LT3188599T (cg-RX-API-DMAC7.html)
MA (1) MA40607B1 (cg-RX-API-DMAC7.html)
MD (1) MD4710C1 (cg-RX-API-DMAC7.html)
ME (1) ME03597B (cg-RX-API-DMAC7.html)
MX (1) MX361741B (cg-RX-API-DMAC7.html)
MY (1) MY187167A (cg-RX-API-DMAC7.html)
NI (1) NI201700024A (cg-RX-API-DMAC7.html)
PE (1) PE20171109A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500392B1 (cg-RX-API-DMAC7.html)
PL (1) PL3188599T3 (cg-RX-API-DMAC7.html)
PT (1) PT3188599T (cg-RX-API-DMAC7.html)
RS (1) RS59751B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701567UA (cg-RX-API-DMAC7.html)
SI (1) SI3188599T1 (cg-RX-API-DMAC7.html)
SV (1) SV2017005400A (cg-RX-API-DMAC7.html)
TN (1) TN2017000040A1 (cg-RX-API-DMAC7.html)
TW (1) TWI639429B (cg-RX-API-DMAC7.html)
UA (1) UA120765C2 (cg-RX-API-DMAC7.html)
UY (1) UY36286A (cg-RX-API-DMAC7.html)
WO (1) WO2016036598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
CN115569119A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
CA3158632A1 (en) 2019-10-24 2021-04-29 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP1768976B1 (en) * 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) * 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések

Also Published As

Publication number Publication date
JP2021080281A (ja) 2021-05-27
TW201613587A (en) 2016-04-16
EP3590338A3 (en) 2020-03-18
CN113577074A (zh) 2021-11-02
JP2018154655A (ja) 2018-10-04
PT3188599T (pt) 2020-01-15
MD20170025A2 (ro) 2017-07-31
PE20171109A1 (es) 2017-08-07
CN107375285A (zh) 2017-11-24
SV2017005400A (es) 2017-04-20
ECSP17019893A (es) 2017-05-31
KR20180085047A (ko) 2018-07-25
IL250692A0 (en) 2017-04-30
PL3188599T3 (pl) 2020-06-01
CR20170121A (es) 2017-07-17
CY1122746T1 (el) 2021-03-12
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
KR102307275B1 (ko) 2021-09-30
CN113577073A (zh) 2021-11-02
BR112017003552A2 (pt) 2017-12-05
MX361741B (es) 2018-12-14
TN2017000040A1 (en) 2018-07-04
NI201700024A (es) 2017-07-18
CN107205389A (zh) 2017-09-26
DOP2017000055A (es) 2017-08-15
MX2017002825A (es) 2017-09-28
AR103118A1 (es) 2017-04-19
MD4710C1 (ro) 2021-04-30
JP2017526695A (ja) 2017-09-14
US20190175574A1 (en) 2019-06-13
KR20170047372A (ko) 2017-05-04
CA2959158A1 (en) 2016-03-10
AU2015312231A1 (en) 2017-03-23
PH12017500392B1 (en) 2018-08-31
EP3188599A1 (en) 2017-07-12
ME03597B (me) 2020-07-20
WO2016036598A1 (en) 2016-03-10
US10894041B2 (en) 2021-01-19
AP2017009772A0 (en) 2017-02-28
TWI639429B (zh) 2018-11-01
UA120765C2 (uk) 2020-02-10
CN109172575A (zh) 2019-01-11
SI3188599T1 (sl) 2020-02-28
EP3590338A2 (en) 2020-01-08
US10278964B2 (en) 2019-05-07
US11723902B2 (en) 2023-08-15
JO3541B1 (ar) 2020-07-05
US20210093627A1 (en) 2021-04-01
JP7044918B2 (ja) 2022-03-30
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
ES2761777T3 (es) 2020-05-21
AU2015312231B2 (en) 2017-10-19
US20240024303A1 (en) 2024-01-25
US20160067236A1 (en) 2016-03-10
CO2017003263A2 (es) 2017-07-28
MY187167A (en) 2021-09-07
PH12017500392A1 (en) 2017-07-17
US20170296526A1 (en) 2017-10-19
KR102234319B1 (ko) 2021-04-01
IL250692B (en) 2019-05-30
HRP20192345T1 (hr) 2020-03-20
NZ729673A (en) 2023-09-29
KR101881264B1 (ko) 2018-07-23
MA40607B1 (fr) 2019-11-29
EP3188599B1 (en) 2019-10-02
UY36286A (es) 2016-02-29
US9675600B2 (en) 2017-06-13
RS59751B1 (sr) 2020-02-28
HUE046894T2 (hu) 2020-04-28
KR20210035923A (ko) 2021-04-01
JP6923486B2 (ja) 2021-08-18
EP3188599A4 (en) 2017-10-11
SG11201701567UA (en) 2017-03-30
MD4710B1 (ro) 2020-09-30
LT3188599T (lt) 2019-12-10
CL2017000494A1 (es) 2017-09-15

Similar Documents

Publication Publication Date Title
JP6356907B2 (ja) アナモレリンに基づく医療
Ceresoli et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Pectasides et al. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non–small-cell lung cancer: A phase II study
HK40020876A (en) Medical treatments based on anamorelin
HK1234959A1 (en) Medical treatments based on anamorelin
HK1234959B (en) Medical treatments based on anamorelin
OA18229A (en) Medical treatments based on anamorelin.
NZ729673B2 (en) Medical treatments based on anamorelin
TW202327596A (zh) 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法
Buxton et al. RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170814

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170814

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180614

R150 Certificate of patent or registration of utility model

Ref document number: 6356907

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153